ロゴマーク：AIRNA
Stanford, US · Founded 2021 · 84 employees on LinkedIn · 9 known investors
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
Also known as AIRNA · Airna Bio
Founders & leadership
ロゴマーク：AIRNA was founded in 2021 by Thorsten Stafforst.
Board
Investors · 9
Reported raises · per SEC filings
Form D private placements$1K disclosed across 1 round · 2021
▶$1KraisedNov 2021 · 3 investors · BiotechnologyRule 506(b)
- Jin (Billy) LiExecutive Officer, Director
- Thorsten StafforstExecutive Officer, Director
- Paul VogelExecutive Officer, Director
- Offering amount
- $1K
- Amount sold
- $1K
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026AIRNA is a biotechnology company developing RNA-editing therapeutics intended to deliver functional cures for patients with rare diseases and common conditions. The company positions its work within the broader field of genetic medicines, describing a pipeline of novel medicines based on precise editing of RNA rather than DNA.
AIRNA's disclosed lead program is AIR-001, a candidate for alpha-1 antitrypsin deficiency (AATD). In preclinical data presented at the ASGCT meeting in May 2026, the company reported that AIR-001 achieved up to 59% precise RNA editing in vivo and restored 40 µM of functional M-AAT in a mouse model of AATD. AIRNA also disclosed cardiometabolic RNA-editing programs, reporting preclinical evidence that RNA editing can introduce protective variants associated with cardiovascular disease and drive reductions in LDL cholesterol levels.
Founding story
Thorsten Stafforst is identified on the company website as a founder of AIRNA, and is quoted on the promise of RNA editing.
Traction
Traction disclosed in available sources is preclinical: AIR-001 data in an AATD mouse model and preclinical cardiometabolic program data presented at a scientific conference in May 2026. No clinical-stage programs, revenue, or headcount figures are disclosed.
Latest developments
In May 2026, AIRNA presented preclinical data on AIR-001 for AATD and on its cardiometabolic RNA-editing programs at the ASGCT meeting. In June 2026, the company appointed Todd Bazemore, described as having more than 30 years of experience leading clinical- and commercial-stage biotechs focused on rare diseases, as President and Chief Executive Officer to lead its next stage of growth.
▸Full profile — market position, technology, go-to-market, geography
Market position
AIRNA describes itself as a biotech company pioneering RNA-editing therapeutics; available sources do not provide comparative market share, competitor, or financing information.
Technology
The company's platform is based on RNA editing, which it describes as a means of making precise changes at the RNA level to produce functional versions of disease-associated proteins. Reported preclinical results include up to 59% precise in vivo editing with AIR-001 and restoration of functional M-AAT protein in an AATD mouse model, as well as editing to introduce protective genetic variants relevant to cardiovascular disease and LDL cholesterol reduction.
Go-to-market
Patients with rare genetic diseases, initially alpha-1 antitrypsin deficiency, and patients with common cardiometabolic conditions such as cardiovascular disease and elevated LDL cholesterol.
Geography
Company communications are issued from Cambridge, Massachusetts, United States.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsAIRNA announced the appointment of Todd Bazemore as President and Chief Executive Officer. The company described him as bringing over 30 years of experience leading clinical- and commercial-stage biotechs with a focus on rare diseases.
AIRNA presented new preclinical data at the ASGCT meeting. The company reported that its alpha-1 antitrypsin deficiency (AATD) candidate AIR-001 achieved up to 59% precise RNA editing in vivo and restored 40 uM functional M-AAT in a mouse model of AATD, and that RNA editing could introduce protective variants for cardiovascular disease and reduce LDL cholesterol levels.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- ロゴマーク：AIRNAairna.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does ロゴマーク：AIRNA do?
- AIRNA is a Cambridge, Massachusetts biotech developing RNA-editing therapeutics for rare and common diseases.
- Who founded ロゴマーク：AIRNA?
- ロゴマーク：AIRNA was founded by Thorsten Stafforst in 2021.
- Who are ロゴマーク：AIRNA's investors?
- ロゴマーク：AIRNA's investors include +ND Capital, ARCH Venture Partners, Forbion, Venrock, Fast Track Initiative, Nextech Invest, Novalis LifeSciences, Ono Venture Investment, Inc. and 1 more.
- How much funding has ロゴマーク：AIRNA raised?
- ロゴマーク：AIRNA has disclosed $1K raised across 1 round.
- Where is ロゴマーク：AIRNA headquartered?
- ロゴマーク：AIRNA is headquartered in Stanford, US.